patients Non Hodgkin ,attending Tumor Center in Merjan medical city, and (30 ) 
This antibody may be used in the study of normal and neoplastic cells of B cell origin, in the study of B cell development, and activation. [6] . ( 13) .
The product of fusion gene may be identified by immunohistochemstry using antiserum to ALK protein.
Probes are available to identify the translocation by fluorescent in situ hybridization. The nucleophosmin component associated with the commonest translocation results in nuclear positivity as well as cytoplasmic positivity. Positivity with the other translocations may be confined to the cytoplasm. [7] .
II.
Patients And Methods.
Fifty (50) patients clinically diagnosed as lymphoma patients, 17 (34%) Hodgkin's and 33 (66%) patients, Non Hodgkin, attending tumor center in merjan medical city and (30) matched age person, as a control group enrolled in this study in the period between Junuary and Augest 2012. Specific diagnosis is clinically done by consultant physician, histopathologist and confirmed by specific marker or Cluster of Differentiation (CD) markers (CD20 and CD30) done by using immunohistochemical technique (IHC) according to manual principle and method of Dakocytomation company [8] . IL-8, IFN-γ, also done by ELISA technique for all patients and control groups , by using manual principle and methods of BioSource Company. [9] .
III. Result And Discussion.
Cytokines level important to monitored the severity of damage and whether the patients with good or bad prognosis , so that recommended to study different types of cytokines for Th1 ,Th2 and NK cell activators. Increased level of interferon is constituent with disease requirement because the interferon used in regulation and maintenance of immunological response, as well as used as therapeutic agent for different diseases from which, is lymphomas. The result of present study shows that a highly significant (P<0.01) increased in mean result of IFN-γ in both groups HL, 682 pg/ml and NHL, 760 pg/ml in compareson with control group, 404.3 pg/ml. as mentioned in " Fig. (1) " . IFNinhibits the activity of Th2 cells, thereby inhibiting antibody synthesis. It is also the most potent activator of macrophages. It stimulates MHC class II expression on macrophage lineage cells and endothelial cells. IFN-γ used as antiviral, antiprolefreative and immunomodulary effects. [10] . Significantly increased CD4+, IFN-gamma producing (Th1) cell percentage were found in untreated lymphoma cases. CD8+ IL-4 and IFN-gamma producing (Tc0) T cell frequency is significantly higher in untreated lymphoma patients compared with normal controls. Patients in long-term remission have lower frequency of CD4+, IL4 producing (Th2) cell, and increased CD4+ IFN-gamma producing (Th1) cell frequency, compared with healthy normal controls. These may contribute to strong polarization toward Th1 type response, needed for lymphoma clearance and remission. [11] .
IL-8 small ,inducible ,secreted cytokines or chemoattractant or super family of low molecular weight proteins. Play an important role as pathogenic mediators in several pathogenesis, inflammatory and autoimmune diseases. IL-8 shows highly significant decreased (P<0.01) in mean concentration in NHL, 143.48 pg/ml as compared with control samples, as well as no significant decreased in mean concentration of HL, 265.1 pg/ml in comparison with control .There is significant increased (P<0.05) in IL-8 level of HL patients compared with NHL. As shown in " Fig. (2) ". Except TNF alpha, significantly higher pretreatment levels of interleukin-2(IL-2), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6) and interleukin-8 (IL-8) were observed in most of Malignant lymphoma (ML) patients at diagnosis or relapse as compared with controls. Cytokine levels declined in responding patients after therapy and there were no differences between, the cytokine levels remained elevated in non responding patients. The elevated IL-8 level correlated with the clinical stage and presenting B symptoms of ML patients and had no correlation with other clinical-hematological parameters. The changes of cytokines may be served as a means to observe the condition of ML patients and supervise their response to treatment. [12] . Cytokines play important roles in the pathogenesis of lymphomas. Elevated levels of IL-6, IL-8 and IL-10 correlated with more adverse disease features. Consequently, patients with elevated IL-6, IL-8 and IL-10 levels prior to treatment had a lower response to therapy. Furthermore, those with elevated IL-6 and IL-10 levels had poor median, 3-year and 5-year survival, while elevated serum IL-8 level did not correlate with overall survival. Worse survival was also confirmed in patients with combined elevated pretreatment serum levels of IL-6, IL-8 and IL-10 . Serum levels of IL-6, IL-8 and IL-10 before treatment of patients with newly diagnosed Diffused large B-cell lymphoma (DLBCL) may give some insight into the possible prognosis and thus facilitate the decisions regarding therapeutic approaches for individual patients. [13] .
Lymphoid immune status contribute with the higher level of such cytokines as a monitor for progressive pathway of diseases. The result of present study shows that, there is a highly association between CD20 with NHL, 29 :33( 87.8%) , CD30 with HL, 12:17 ( 70.8%) as shown in " Fig. (3) ". CD30, is glycoprotein, expressed in only a small population of normal lymphoid tissue. By contrast, it is expressed in approximately 50% of all malignant lymphomas including all cases of Hodgkin's disease and a vast majority of anaplastic large cell lymphomas. Antigen can be detected in sera from lymphoma patients, but not in sera from normal individuals with systemic infection. The CD20 antigen, glycoprotein found on all B cells in peripheral blood, lymph node, spleen, tonsil, and bone marrow, normal cells do not express the CD20 antigen. This antibody may be used in the study of normal and neoplastic cells of B cell origin, in the study of B cell development, and activation. [6] CD30 (Ki-1 antigen), a 120 kD single chain glycoprotein, is expressed in only a small population of normal lymphoid tissue. By contrast, it is expressed in approximately 50% of all malignant lymphomas including all cases of Hodgkin's disease and positive anaplastic large cell lymphomas. Ki-1 antigen can be detected in sera from lymphoma patients, but not in sera from normal individuals with systemic infection. The antibody reacts with a formalin-resistant intracytoplasmic epitope found in the majority of B cells which is now considered to be the CD20 antigen, a pan-B cell marker. The antibody primarily recognizes a polypeptide B cell component and also a minor cellular antigen. The staining pattern is consistent with pan-B reactivity, producing staining for B cells in lymphoid and peripheral blood tissue. This antibody may be used in the study of normal and neoplastic cells of B origin, in the study of B cell development and activation [14] . V.
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Conclusion.
Present study concluded the fact that cytokines level important to monitored the severity of damage and whether the patients with good or bad prognosis, and refer to important of study other different types of cytokines for Th1, Th2, and NK cell activators, such as ( IL-10 , IL-2 and IL-12) to predict of ability to producing pro-inflammatory and anti-inflammatory mediators as well as ability to treatment of such diseases.
Animal models and human studies clearly demonstrate that a physiological role of the immune system is to prevent tumor growth. It is generally assumed that most spontaneous tumors, arising with very long latency times, are indeed poorly immunogenic. Starting with innate immunity, macrophages and other phagocytes are important because they can directly destroy tumor cells and also because they can produce tumor cell fragments that can be picked up by antigen presenting cells. NK cells kill tumor cells with a low MHC expression; they are the sole leukocyte type active in the bloodstream, hence they have an important role in the defense against circulating metastatic cells.
